Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the…
Read More...
Read More...
